News

Semaglutide: A Promising Frontier in Alzheimer's Disease Prevention

Views: 44     Author: Unibest Industrial     Publish Time: 2024-10-25      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

At Unibest, we're committed to advancing pharmaceutical solutions that make a real difference in people's lives. Today, we're excited to discuss groundbreaking research on semaglutide, the blockbuster medication that's showing promising potential in the fight against Alzheimer's disease (AD).


Semaglutide ability to protect against AD



Semaglutide: More Than Just a Diabetes Treatment

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been primarily known for its effectiveness in treating type 2 diabetes and obesity. In the SELECT trial, it has shown cardiovascular benefits in reduceing cardiovascular events in overweight and obese individuals with established atherosclerotic cardiovascular disease (ASCVD) but without diabetes. However, recent research suggests its benefits may extend far beyond these conditions.



New Research Highlights Semaglutide's Potential in AD Prevention

A large-scale study published in Alzheimer's & Dementia has revealed exciting findings about semaglutide's potential role in preventing Alzheimer's disease. The study, which analyzed data from over 1 million patients with type 2 diabetes, found that:

  • Semaglutide was associated with a 40% to 70% reduced risk of first-time AD diagnosis compared to other antidiabetic medications.

  • This protective effect was observed across different patient groups, regardless of obesity status, gender, or age.

  • Patients taking semaglutide also had significantly lower rates of AD-related medication prescriptions.



Why This Matters

With AD affecting millions worldwide and no cure currently available, these findings offer a ray of hope. The potential of semaglutide to delay or prevent AD could revolutionize how we approach this devastating disease.



Unibest: At the Forefront of Semaglutide Development

As a leading partner in the pharmaceutical industry, Unibest is proud to be at the forefront of semaglutide development. We provide:

Semaglutide Tablet Project Proposal

View our Semagcare Project Brochure for Detail



Our commitment to innovation and quality ensures that we're well-positioned to support further research and development in this exciting area.


Looking Ahead

While these findings are promising, more research is needed. Clinical trials are currently underway to further explore semaglutide's neuroprotective effects in early AD. As a key player in pharmaceutical development, Unibest is excited to contribute to this potentially game-changing field of research.


Stay tuned for more updates on semaglutide and other innovative pharmaceutical solutions from Unibest. Together, we're working towards a future where diseases like Alzheimer's can be effectively prevented and treated.



Reference

Wang W, Wang QQ, Qi X, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's Dement. 2024; 1-12. https://doi.org/10.1002/alz.14313